At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Nov 9, 2026 at 06:30 ET
Abeona Therapeutics acquires ABO-801 (formerly APT-1011), a Phase 3-ready oral therapy for eosinophilic esophagitis, from Ellodi Pharmaceuticals for $20M in stock with no upfront cash, plus up to $60M in milestones and tiered royalties. Concurrently, the company raises $30M in a PIPE financing at $3.75/share, with participation from leading life sciences investors. The deal diversifies Abeona's pipeline beyond its commercial gene therapy ZEVASKYN, but the PIPE dilutes existing holders by ~25% and the activist stake (6.1% from October 23) adds governance pressure.
- Acquired ABO-801 (EoE candidate) from Ellodi for $20M in stock, no upfront cash; up to $30M FDA approval milestone, $30M sales milestones, and low-to-mid teen royalties.
- ABO-801 has FDA Orphan Drug and Fast Track designations; two Phase 3 studies completed (neither met co-primary symptom endpoint, but showed histologic/endoscopic activity).
- Planned Phase 3 study initiation mid-2027; topline results expected by end of 2028.
- PIPE financing: $30M gross proceeds from 6.4M shares at $3.75/share and pre-funded warrants for 1.6M shares at $3.7499.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access